However, since negative results have been reported with the addition of trastuzumab or pertuzumab to chemotherapy in patients with HER2-low BC [13], HER2-low BC were not eligible for anti-HER2 monoclonal antibodies. This evidence concerns the gene ERBB2 and breast cancer.